Biosimilar Inspection Modernization Act of 2025
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- Senate
- Sponsors
- 2
- Latest action
- Dec 16, 2025
What it does
The Biosimilar Inspection Modernization Act of 2025 would require the FDA to modernize its inspection processes for facilities that manufacture biosimilar biological products by holding a public meeting and issuing a report on expanding the use of mutual recognition agreements for inspections, updating inspection tools to increase remote assessments and alternative methods, and developing a strategic plan to improve domestic inspections—including staff recruitment, internal communication, and coordination with product sponsors. The bill affects biosimilar biological product establishments registered with the FDA and aims to enhance inspection efficiency and effectiveness through risk-based,…
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.